Survival

CDK4/6 Inhibitor Plus Aromatase Inhibitor Improves Progression-Free Survival in Metastatic Breast Cancer

CDK4/6 Inhibitor Plus Aromatase Inhibitor Improves Progression-Free Survival in Metastatic Breast Cancer

By

Adding ribociclib to letrozole significantly improves progression-free survival for postmenopausal women with metastatic hormone receptor (HR)-positive breast cancer, compared with hormone therapy alone.

Daratumumab With Len-Dex Prolongs PFS in R/R Multiple Myeloma

Daratumumab With Len-Dex Prolongs PFS in R/R Multiple Myeloma

By

Adding daratumumab to lenalidomide and dexamethasone significantly prolonged progression-free survival compared with lenalidomide plus dexamethasone alone in patients with relapsed or refractory multiple myeloma.

Outcomes Are Better for HPV16-Associated Oropharyngeal Cancer, but Not for Other HPV Strains

Outcomes Are Better for HPV16-Associated Oropharyngeal Cancer, but Not for Other HPV Strains

By

Patients with oropharyngeal tumors that harbor HPV16 have higher 5-year survival and lower recurrence rates than patients with tumors that harbor other HPV strains or are HPV-negative.

SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC

By

Continued adoption of stereotactic body radiation therapy (SBRT) to treat early stage NSCLC improved OS and lung cancer-specific survival, according to a study presented at the 2016 annual meeting of the American Society for Radiation Oncology.

Adding Bevacizumab to Adjuvant Capecitabine Not Effective for mCRC

By

The combination of adjuvant bevacizumab and capecitabine failed to improve disease-free survival compared with capecitabine alone in patients with mCRC who had undergone potentially curative surgery.

Immune Cells Are Biologically Older After Hematopoietic Cell Transplantation

Immune Cells Are Biologically Older After Hematopoietic Cell Transplantation

By

Hematopoietic stem cell transplantation (HCT) is found to increase expression of a genetic code used to make proteins, leading to a biological aging of immune cells equivalent to 30 years of chronological age.

Outcomes in Patients With Brain Metastasis from Esophageal Carcinoma

Outcomes in Patients With Brain Metastasis from Esophageal Carcinoma

[Journal of Gastrointestinal Oncology] This research examines factors associated with survival in patients with brain metastasis from esophageal cancer.

HIV Infection Worsens Survival of Patients With Cervical Cancer

HIV Infection Worsens Survival of Patients With Cervical Cancer

By

HIV is associated with reduced cancer-specific survival among women with invasive cervical cancer.

Addition of Elotuzumab to Bortezomib/Dexamethasone Improves Survival in Relapsed/Refractory Multiple Myeloma

Addition of Elotuzumab to Bortezomib/Dexamethasone Improves Survival in Relapsed/Refractory Multiple Myeloma

By

The addition of elotuzumab to bortezomib/dexamethasone appears to increase progression-free survival in relapsed/refractory multiple myeloma (RRMM).

In NSCLC, Erlotinib Appears Effective at Doses Lower Than MTD

In NSCLC, Erlotinib Appears Effective at Doses Lower Than MTD

By

Patients with metastatic non-small cell lung cancer demonstrated prolonged median progression-free survival with the administration of erlotinib below the maximum tolerated dose.

Metformin Use May Improve Survival in Patients With CRC, Diabetes

By

Research indicates that metformin can confer improved survival for patients with colorectal cancer that also have diabetes.

Adding Daratumumab to Lenalidomide/Dexamethasone Improves Survival in Multiple Myeloma

Adding Daratumumab to Lenalidomide/Dexamethasone Improves Survival in Multiple Myeloma

By

Treatment with daratumumab, lenalidomide, and dexamethasone (DRd) may be superior to lenalidomide and dexamethasone (Rd) alone in patients with relapsed or refractory multiple myeloma.

CML-CP: Dasatinib, Nilotinib Associated With Similar Survival Outcomes as Frontline Therapy

CML-CP: Dasatinib, Nilotinib Associated With Similar Survival Outcomes as Frontline Therapy

By

Dasatinib and nilotinib are associated with similar response rates and survival outcomes in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP).

ADT May Reduce Survival in African American Men With Favorable-risk Prostate Cancer

ADT May Reduce Survival in African American Men With Favorable-risk Prostate Cancer

By

Use of androgen suppression therapy may negatively impact survival in African American patients with favorable-risk prostate cancer.

Age-Related Prognosis in Breast Cancer Varies by Subtype

Age-Related Prognosis in Breast Cancer Varies by Subtype

By

Survival among women age 40 years and younger with breast cancer appears to vary according to breast cancer subtype, with age particularly prognostic for women with luminal type breast cancers.

Salvage Radiotherapy at Lower PSA Levels May be Beneficial

Salvage Radiotherapy at Lower PSA Levels May be Beneficial

By

As salvage radiotherapy (SRT) outcomes may be affected by factors associated with prostatectomy findings, they may be positively affected when used at lower prostate-specific antigen (PSA) levels.

Adjuvant Therapy Improves Survival in Stage II Colon Cancer, Study Confirms

By

A very large retrospective study of patients with stage II colon cancer found adjuvant therapy improves survival, regardless of treatment regimen, patient age, or high-risk pathologic risk features.

Telomere Length Predicts Risk for Delayed Recovery in Pediatric Patients With AML

Telomere Length Predicts Risk for Delayed Recovery in Pediatric Patients With AML

By

Telomere length is predictive for determining which children treated for AML are at highest risk for delayed recovery, a finding that may have significant implications for treatment-related morbidity and mortality.

Moderate-to-Vigorous Exercise Improves Subjective Memory in Breast Cancer Survivors

Moderate-to-Vigorous Exercise Improves Subjective Memory in Breast Cancer Survivors

By

Memory problems in breast cancer survivors appear associated with the high stress load these patients experience rather than their treatment, and moderate-to-vigorous physical activity may help subjective memory in these patients.

Nonsolid Nodules Unlikely to Cause Death in Lung Cancer

Nonsolid Nodules Unlikely to Cause Death in Lung Cancer

Lung cancers that manifest as nonsolid nodules seem to have indolent course, according to recent research data.

Many Older Women With Early Stage Breast Cancer Are Susceptible to Functional Decline After Starting Treatment

By

Approximately 20% of older women with stage I-III breast cancer lost the ability to complete some basic tasks of independent living within 1 year of starting treatment. However, an assessment tool can identify those women at greatest risk of posttreatment functional decline.

Extent of Resection Influences Length of Progression-Free Survival in Glioblastoma

Extent of Resection Influences Length of Progression-Free Survival in Glioblastoma

By

Gross total resection to treat glioblastoma multiforme (GBM) showed progression-free survival benefits over subtotal resection and biopsy in a meta-analysis of 37 studies.

Autologous Stem Cell Transplant Safe as Standard of Care in Patients With HIV-Associated Lymphoma

Autologous Stem Cell Transplant Safe as Standard of Care in Patients With HIV-Associated Lymphoma

By

Recent results from a multicenter, phase 2 trial suggest that patients with HIV and aggressive lymphoma should receive autologous stem cell transplant as standard of care. Risk of serious complications after transplant in these patients is equal to that of patients without HIV.

Overall Survival and Progression-Free Survival Are Improved With Ibrutinib for del17p CLL

Overall Survival and Progression-Free Survival Are Improved With Ibrutinib for del17p CLL

By

Ibrutinib treatment for chronic lymphocytic leukemia with the deletion of chromosome 17p (del17p CLL) increases the percentage of patients alive at 30 months over other therapies for del17p CLL.

Novel Antibody-Drug Conjugate Bridges Patients With Relapsed ALL to Stem Cell Transplant

Novel Antibody-Drug Conjugate Bridges Patients With Relapsed ALL to Stem Cell Transplant

By

In a randomized phase III study of the drug inotuzumab ozogamicin, a statistically significant percentage of patients with ALL whose disease had relapsed following standard therapies, qualified for stem cell transplants after treatment with the drug.

Intensive Protocol Improves Survival for Adults with Acute Lymphoblastic Leukemia

Intensive Protocol Improves Survival for Adults with Acute Lymphoblastic Leukemia

By

Event-free survival for adult patients with ALL has improved from 40% to 73% with the implementation of the NOPHO ALL 2008 protocol in July 2008.

Adjuvant Chemotherapy Improves Overall Survival in Early Stage NSCLC

By

Adjuvant chemotherapy in patients with stage Ib non-small cell lung cancer improved overall survival and 5-year overall survival.

Number of Ovarian Cancer Cases Not Treated Surgically or Not Treated at All Is Increasing

Number of Ovarian Cancer Cases Not Treated Surgically or Not Treated at All Is Increasing

By

The number of patients older than 75 years who do not undergo surgery is increasing, especially among those with stage III or IV ovarian cancer. Approximately 50% do not undergo surgery and 25% receive no treatment at all.

New Therapy Blocks Breast Cancer Cells From Entering and Hiding in Bone Marrow to Form Latent Metastases

New Therapy Blocks Breast Cancer Cells From Entering and Hiding in Bone Marrow to Form Latent Metastases

By

Researchers demonstrate how breast cancer cells invade bone marrow, where they escape chemotherapy and hormonal therapies that would otherwise eliminate the cancer cells.

Metastatic Ability May Precede Tumor Formation in Pancreatic Cancer

Metastatic Ability May Precede Tumor Formation in Pancreatic Cancer

By

Metastatic capabilities of pancreatic cancer might arise before tumors even form. Metastasis and advanced stage of disease at diagnosis are attributed to low survival rates for pancreatic cancer.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs